H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $115 and keeps a Buy rating on the shares after the company reported that the Phase 3 ROSELLA study evaluating relacorilant as a combination therapy with nab-paclitaxel to treat platinum-resistant, recurrent ovarian cancer had met its primary endpoint. The firm projects relacorilant to generate risk-adjusted ovarian cancer related revenues of $1.2B in 2030, growing from $126,000 in 2026, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics announces ROSELLA trial meets primary endpoint
- Corcept Therapeutics: Promising Clinical Trial Results and Strategic Positioning Drive Buy Rating
- Corcept Therapeutics initiates Momentum trial to treat resistant hypertension
- Corcept Therapeutics: Strong Buy Rating Driven by NDA Acceptance and Promising Trial Outcomes
- FDA files Corcept’s NDA for Relacorilant as treatment in Hypercortisolism